webinar recording available - register to watch

Driving down the cost: Optimising CGT with the right CDMO partner

High manufacturing costs remain one of the most significant barriers to the success of cell and gene therapies, limiting patient access. By partnering with CDMOs that offer both technical expertise and operational excellence, biotech companies can reduce costs while accelerating development and commercialisation.

Experts from OXB will explore how the right partnership can unlock savings across the value chain, accelerate timelines, and ensure regulatory confidence. Attendees will learn practical approaches to identifying the best-fit CDMO partner to achieve both near-term efficiency and long-term success.

Attendees will learn about:
  • The primary cost drivers in cell and gene therapy manufacturing
  • A case study demonstrating how a CDMO leveraged platform data to reach GMP faster
  • How CDMOs create value beyond capacity through expertise, innovation, and scale
  • How to evaluate and select the best CDMO partner to drive cost efficiency and long- term success
watch now
watch the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

Mark Caswell

Mark Caswell

Site Head of UK Operations, OXB

Mark S. Caswell is a senior biotech management professional with more than 23 years of leadership experience and over 27 years in cGMP operations, design, construction, startup, commissioning, and qualification. He has a proven track record of guiding complex, innovative, and diverse organizations across multiple modalities, including mammalian, antibody-drug conjugates, cell, gene, viral therapies, and mRNA production. Mark combines deep technical expertise with strong people leadership to ensure safety, quality, and regulatory compliance while driving operational excellence.

Chris Gray

Chris Gray

VP, Head of Manufacturing & MSAT, OXB

Chris joined OXB in July as Vice President, Head of Manufacturing & MSAT. Responsible for delivering significant increases in throughput and building a lean team focused on delivery in the competitive CDMO space. Prior to working for OXB. Chris was Senior Vice President of Technical Operations & Site General Manager for Autolus Therapeutics, responsible for manufacturing activity at the Stevenage site. This includes Production, Engineering, Supply Chain, Patient Scheduling, Training & Validation functions. As an experienced Operations Lead with more than 20 years' experience in the Biotech / Pharmaceutical industry Chris has been leading Production and Supply Chain teams delivering significant change initiatives.

Nicholas Clarkson

Nicholas Clarkson

VP, Head of Process Development, OXB

Nick Clarkson has over 20 years’ experience in research and development in cell and gene therapy and immunology and is currently Vice President and Head of Process Development at OXB which is a world leading viral vector CDMO. He has held senior leadership roles in innovation and analytical development, giving him a breadth of experience spanning basic research and development in viral vector manufacturing platforms, through to scale up for GMP manufacturing and validation for commercial products.

Jaime Green

Jaime Green

Freelance Journalist & Science Writer

Jaime Green is a freelance science writer and author. Her work has appeared in The New York Times Magazine, The Atlantic, Aeon, Popular Science, Slate, Astrobites, and elsewhere. She is the series editor of The Best American Science and Nature Writing and author of The Possibility of Life: Science, Imagination, and Our Quest for Kinship in the Cosmos.